Biocon said its subsidiary Biocon Biologics has received the Drugs Controller General of India’s (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb to reduce pro- inflammatory cytokines levels in confirmed ovid-19 patients admitted to ICU with confirmed or imminent respiratory failure.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/36zmCPQ
